Pharmacovigilance Market by Product Type, Distribution Channel, End User 2024-2032
                     Global Pharmacovigilance 
Market Research and 
Forecast Report 2024-
2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
Accord ing  t o  t he  la tes t  repor t  by  I MARC Group,  t i t l ed  "Pharmacovi g i lance  
Market :  G l oba l  Indust ry  T rends ,  Share ,  S ize ,  Growth ,  O pportun i ty  and  
Forecast  2024-2032 , "  t he  g loba l  pharmacov ig i l ance  marke t  s i ze  reached  US$  7 . 9  
B i l l i on  in  2023 .
Report Pharmacov ig i lance  (PV)  i s  t he  pharm aco log ica l  sc ience  o f  s t udy ing  t he  de t ec t i on ,  
assessmen t ,  and  prevent ion  o f  un f avo rab le  e f fec ts  o f  pha rmaceu t i ca l  m ed ic ines .  
Highlight and I t  p lays  a  c r i t i ca l  r o l e  in  i den t i f y i ng  p rev ious ly  unknown ADR (adve rse  d rug  reac t ions )  and drug  tox ic i t y ,  de te rm in ing  changes  in  f r equency  o r  seve r i t y ,  and  
assess ing  t he  r i sks  and benef i t s  o f  d rugs  to  de te rm ine  requ i red  ac t i ons .  
Description I t  a l so  assures  t he  accu racy  o f  commun ica t ed  i n fo rmat ion  t o  hea l thca re  
p ro f ess iona ls  and  pa t ien ts .  As  a  resu l t ,  PV  i s  w ide ly  used t o  comprehend the  
e f fec ts  o f  d rugs  on  i nd iv idua ls  ac ross  the  g lobe .
Request  fo r  a  PDF sample  o f  th is  repor t :  
ht tps : / / www. imarcgroup .com/pharmacov ig i l ance-marke t / reques t samp le
Report Description
G l ob a l  Ph arm acov i g i l ance  M ark e t  T rend s :
The  m ar k e t  i s  p r im ar i l y  d r i v en  b y  t he  r i s i ng  p r eva l ence  o f  c h r on i c  d i s eases ,  such  as  d iabe t e s ,  hy pe r t ens ion ,  onc o log i ca l  
d i seas es ,  and  ca r d iac  d i so r d e r s ,  r e su l t i n g  i n  t he  i nc r eas in g  consu m pt ion  o f  d r ugs  wo r ldw ide .  I n  add i t i on ,  t h e  i n t r od uc t i on  
o f  advan ced  p la t f o r m s  t o  en su r e  au t om a t ed  ADR  r ep o r t i n g  i s  c on t r i bu t i ng  t o  m ar k e t  g r ow t h .  M or eov e r ,  t he  sudd en  
ou t b r eak  o f  co r on av i r us  d i sease  ( C O VI D - 19 )  an d  t h e  co nseq uen t  nec ess i t y  f o r  vacc ina t io n  has  a l so  c r ea t ed  s eve r a l  
oppo r t un i t i es  f o r  t he  m ar k e t  p laye r s .  Th i s ,  cou p led  w i t h  t he  w id esp r e ad  ad op t i on  o f  ne w t e chno l og ies  i n  c l i n i c a l  r ese a r ch ,  
such  as  t he  i n co r po r a t i o n  o f  v i r t u a l  se r v i ces  i n  t he  c l i n i ca l  t r i a l  p r o t oc o l ,  i s  aug m en t ing  t he  m ar ke t  g r o w t h .  
Bes ide s  t h i s ,  l ea d ing  com p an ies  a r e  unde r t ak i ng  va r i ous  i n i t i a t i ves  t o  con duc t  c l i n i c a l  t r i a ls  and  ge ne r a t e  awa r enes s  
abou t  t he  p r o pe r  u t i l i za t i o n  o f  m ed ic ines ,  wh ich  i s  f ac i l i t a t i ng  t h e  m ar ke t  g r ow t h .  A long  w i t h  t h i s ,  ex t e ns i ve  r esea r ch  a nd  
deve lo pm e n t  ( R&D)  ac t i v i t i es  condu c t ed  by  m a jo r  pha r m ac eu t i c a l  and  b io t echn o log i c a l  co m pan ies  t o  de ve lop  new d r u gs  
a r e  p r ov i d i ng  a  pos i t i ve  t h r us t  t o  t he  m ar k e t  g r ow t h .
Look i ng  f o rw ar d ,  I M A RC G r oup  ex pec t s  t he  ma rke t  va l u e  t o  reac h  US$  1 5 . 9  B i l l i on  by  2032 ,  exh i b i t i ng  a  CAG R o f  
7 . 8%  dur i ng  t he  f o rec as t  p er i od  ( 2 02 4 - 20 32 ) .
V i ew  Repo r t  T O C,  F i g ures  and  T ab l e s :  h t t ps : / / w w w . i mar cgrou p . com / ph arma cov i g i l an ce - m ark e t
Breakup by Service Provider:
• In-house
• Contract Outsourc ing
 
Breakup by Product Life Cycle:
• Pre-c l in ical
• Phase I
Report 
• Phase I I
Segmentation • Phase I I I
• Phase IV
Breakup by Type:
• Spontaneous Report ing
• Intens ifi ed ADR Report ing
• Targeted Spontaneous Report ing
• Cohort  Event Monitor ing
• EHR Mining
Breakup by Process Flow:
• Case Data Management
o Case Logging
o Case Data Analysis
Report 
o Medical Reviewing and Reporting
Segmentation • Signal  Detect ion
o Adverse Event Logging
o Adverse Event Analysis
o Adverse Event Review and Reporting
• Risk Management System
o Risk Evaluation System
o Risk Mit igat ion System
Breakup by Therapeutic Area:
• Oncology
• Neurology
• Cardiology
Report • Respiratory Systems
Segmentation • Others
Breakup by End Use:
• Pharmaceuticals Companies
• Biotechnology Companies
• Medical  Device Companies
• Others
Breakup by Region:
• North America
• Asia-Pacifi c
• Europe
• Latin America
• Middle East and Afr ica
Report 
Segmentation
• Accenture plc
• ArisGlobal LLC
• BioCl inica Inc. (Cinven Partners LLP)
•
Competitive Capgemini
• Cognizant
Landscape • International  Business Machines 
with Key Corporation
• ICON plc.
Players • IQVIA Inc.
• ITCl inical
• Parexel International  Corporation
• Wipro Limited
How has the global pharmacovigilance market 
performed so far and how will it perform in the coming 
years?
What has been the impact of COVID-19 on the global 
pharmacovigilance market?
What are the key regional markets?
Key 
Questions What is the breakup of the market based on the service 
provider?
Answered in 
What is the breakup of the market based on the product 
the Report life cycle?
What is the breakup of the market based on the type?
What is the breakup of the market based on the process 
flow?
What is the breakup of the market based on the 
therapeutic area?
What is the breakup of the market based on the end 
use?
What are the various stages in the value chain of the 
industry?
Key What are the key driving factors and challenges in the industry?
Questions 
What is the structure of the global pharmacovigilance 
Answered in market and who are the key players?
the Report What is the degree of competition in the industry?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
        2 . 4 . 1     B o t t o m - U p  A p p r o a c h
Table of         2 . 4 . 2     T o p - D o w n  A p p r o a c h    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
    4 . 1     O v e r v i e w
Contents     4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  P h a r m a c o v i g i l a n c e  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  S e r v i c e  P r o v i d e r
    6 . 1     I n - h o u s e
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  M a r k e t  F o r e c a s t
    6 . 2     C o n t r a c t  O u t s o u r c i n g
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  M a r k e t  F o r e c a s t
7    M a r k e t  B r e a k u p  b y  P r o d u c t  L i f e  C y c l e
    7 . 1     P r e - c l i n i c a l
        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t
       
    7 . 2     P h a s e  I
        7 . 2 . 1  M a r k e t  T r e n d s
        7 . 2 . 2  M a r k e t  F o r e c a s t
    7 . 3     P h a s e  I I
        7 . 3 . 1  M a r k e t  T r e n d s
        7 . 3 . 2  M a r k e t  F o r e c a s t
    7 . 4     P h a s e  I I I
        7 . 4 . 1  M a r k e t  T r e n d s
        7 . 4 . 2  M a r k e t  F o r e c a s t
    7 . 5     P h a s e  I V
Table of         7 . 5 . 1  M a r k e t  T r e n d s        7 . 5 . 2  M a r k e t  F o r e c a s t
8    M a r k e t  B r e a k u p  b y  T y p e
    8 . 1     S p o n t a n e o u s  R e p o r t i n g
Contents         8 . 1 . 1  M a r k e t  T r e n d s
        8 . 1 . 2  M a r k e t  F o r e c a s t
    8 . 2     I n t e n s i f i e d  A D R  R e p o r t i n g
        8 . 2 . 1  M a r k e t  T r e n d s
        8 . 2 . 2  M a r k e t  F o r e c a s t
    8 . 3     T a r g e t e d  S p o n t a n e o u s  R e p o r t i n g
        8 . 3 . 1  M a r k e t  T r e n d s
        8 . 3 . 2  M a r k e t  F o r e c a s t
    8 . 4     C o h o r t  E v e n t  M o n i t o r i n g
        8 . 4 . 1  M a r k e t  T r e n d s
        8 . 4 . 2  M a r k e t  F o r e c a s t
    8 . 5     E H R  M i n i n g
        8 . 5 . 1  M a r k e t  T r e n d s
        8 . 5 . 2  M a r k e t  F o r e c a s t     
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
ht t ps : / /w ww. i ma rc gro up . c o m /p ha rm a c o v i g i l a nc e -m a rke t / t o c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: